Commentary

Takeovers refocus Sanofi on rare diseases

Read more

How GMO rules affect gene and cell therapies

Read more

The case for optimism for Europe's biotech sector

Read more

The three waves of gene therapy

Read more

Building multifunctional biologics to treat disease

Read more

Novel immunotherapy arises from collaboration

Read more

Working with patients to accelerate drug development

Read more

Case study - the merits of adaptive trial design

Read more

Ipsen aspires to role as speciality oncology player

Read more

New body for regenerative medicine launched

Read more